Neuronetics, Inc. Q1 2026 Earnings Call Summary

Neuronetics, Inc. Q1 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

New CEO Dan Reuvers is conducting a comprehensive 'listening tour' to evaluate the integrated NeuroStar and Greenbrook business model following shareholder calls for a strategic separation. Q1 revenue growth of 8% was primarily driven by a 15% increase in U.S. clinic revenue, specifically fueled by continued strength in SPRAVATO treatment volumes and 'buy-and-bill' expansion. NeuroStar system shipments increased 10% year-over-year to 34 units, though treatment session revenue declined 5% due to a reduction in customer inventory levels. TMS volumes within Greenbrook clinics were modestly below prior-year levels, which management attributed to weather disruptions in the Northeast and a shift in the cadence of marketing spend. Management is piloting expanded commercial models for NeuroStar to reach customer segments that require different levels of support than the company's historically comprehensive service model. Gross margin compression to 46.9% was driven by revenue mix, as lower-margin clinic revenues represented a larger portion of total sales compared to the prior year.

Outlook and Strategic Initiatives

Full-year 2026 revenue guidance is maintained at $160 million to $166 million, with operating cash flow expected to be flat to positive in the second half of the year. The company implemented cost-alignment steps in Q1 expected to deliver annualized savings of $2.5 million to $3 million, with net savings beginning in the third quarter. Management expects to return to typical TMS volume trends in the second quarter as patient flow normalized following early-quarter weather disruptions. The company is positioning Greenbrook as a primary delivery site for pending psilocybin therapies, leveraging existing SPRAVATO infrastructure for certified settings and back-office support. A comprehensive search is underway for a new CFO following the departure of Steve Fansteel, with the CEO seeking a partner to lead the company's next growth chapter.

Risk Factors and Structural Changes

The company amended its debt agreement with Perceptive Advisors in March 2026, making a one-time $5 million principal payment to reduce outstanding obligations and interest expense. Cash and cash equivalents declined to $19 million as of March 31, though management believes current liquidity is sufficient to reach the goal of second-half cash flow positivity. Recent UHC and Optum policy changes allowing nurse practitioners to deliver TMS are expected to expand the target account list in 26 states where reimbursement was previously limited. Management acknowledged shareholder frustration regarding valuation and stated they are evaluating the business with an 'open mind' regarding potential structural changes.

Story Continues

Q&A Highlights

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Liquidity and cash runway through year-end 2026

Management projects a full-year cash burn midpoint of $15 million, which would leave approximately $14 million in cash at year-end. The plan assumes the business becomes flat to cash flow positive in the second half of the year, providing sufficient headroom under current debt covenants.

Strategic rationale for the integrated clinic and device model

CEO Reuvers is pragmatically evaluating whether the integrated model or a separation of the TMS business unlocks more value, noting he is not wed to a predetermined conclusion. He emphasized that improving NeuroStar's 'go-to-market menu' is a priority to ensure the company is not 'under punching its weight' in the total addressable market.

Impact of weather and inventory on TMS session revenue

While absolute treatment utilization was up low single digits, revenue was impacted by customers working through existing inventory. TMS patients require daily visits, making the business more sensitive to weather disruptions than episodic therapies like SPRAVATO.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments